share_log

Redhill Biopharma | 424B5: Prospectus

SEC announcement ·  Apr 2 16:12
Summary by Moomoo AI
Redhill Biopharma Ltd. (Redhill), a specialty biopharmaceutical company, has announced the offering of 2,144,487 American Depositary Shares (ADSs) representing 857,794,800 ordinary shares, along with warrants to purchase up to an equivalent number of ADSs. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Registration No. 333-258259. The combined purchase price for each ADS and accompanying warrant is $0.58289. The warrants, offered with the ADSs, are immediately exercisable at a price of $0.75 per ADS and will expire five years from the issuance date. Redhill has stated that there is no established public trading market for the warrants and does not expect one to develop. The ADSs issuable upon exercise of the warrants are also being offered by the prospectus...Show More
Redhill Biopharma Ltd. (Redhill), a specialty biopharmaceutical company, has announced the offering of 2,144,487 American Depositary Shares (ADSs) representing 857,794,800 ordinary shares, along with warrants to purchase up to an equivalent number of ADSs. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Registration No. 333-258259. The combined purchase price for each ADS and accompanying warrant is $0.58289. The warrants, offered with the ADSs, are immediately exercisable at a price of $0.75 per ADS and will expire five years from the issuance date. Redhill has stated that there is no established public trading market for the warrants and does not expect one to develop. The ADSs issuable upon exercise of the warrants are also being offered by the prospectus supplement. The ADSs are listed on The Nasdaq Capital Market under the symbol 'RDHL.' The last reported sale price of the ADSs on Nasdaq was $0.5299 per ADS as of March 28, 2024. The company plans to use the net proceeds from the offering for working capital, acquisitions, and general corporate purposes. The date of the prospectus supplement is March 29, 2024.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more